DISPOSITION OF BRB-I-28 (7-BENZYL-7-AZA-3-THIABICYCLO[3.3.1]NONANE HYDROPERCHLORATE), A NOVEL ANTIARRHYTHMIC AGENT

被引：6

作者：

ALAVI, FK ^{[1
]}

CLARKE, CR ^{[1
]}

SANGIAH, S ^{[1
]}

BERLIN, KD ^{[1
]}

ZISMAN, SA ^{[1
]}

CHEN, CL ^{[1
]}

GARRISON, G ^{[1
]}

SCHERLAG, BJ ^{[1
]}

LAZZARA, R ^{[1
]}

机构：

[1] OKLAHOMA STATE UNIV,COLL VET MED,DEPT PHYSIOL SCI,STILLWATER,OK 74078

来源：

DRUG INVESTIGATION | 1991年 / 3卷 / 05期

关键词：

D O I：

10.1007/BF03259745

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

The aim of this study was to characterise the pharmacokinetic disposition and tissue distribution of BRB-I-28 (7-benzyl-7-aza-3-thiabicyclo[3.3.1]nonane hydroperchlorate) in rats. The pharmacokinetic disposition was studied by collecting blood samples before and at frequent intervals after intracardiac or oral administration of C-14-labelled BRB-I-28. Two-compartment and 1-compartment pharmacokinetic models were used to describe blood concentration-time profiles after intracardiac and oral administration, respectively. After intracardiac administration, the half-life of elimination (t1/2-beta)from blood ranged from 4.66 to 9.91 hours and the apparent volume of distribution (Vd(area)) ranged from 3.131 to 6.239 L/kg. Oral dosing resulted in rapid and extensive absorption (bioavailability +/- 80%). Distribution of radioactivity into heart, kidney, brain, liver, and perirenal fat was measured by sacrificing rats at various time intervals after oral administration of C-14-labelled BRB-I-28. Extensive distribution of radioactivity occurred in highly perfused organs, particularly liver, kidney and heart. However, levels of radioactivity in brain were low.

引用

页码：317 / 323

页数：7

共 15 条

[1]

Akaike H., A new look at the statistical model identification, Institute of Electrical and Electronics Engineers (IEEE) Transactions on Automatic Control, 19 AC, pp. 716-723, (1974)

[2]

Bailey B.R., Berlin K.D., Holt E.M., Scherlag B.J., Lazzara R., Et al., Synthesis, conformational analysis, and antiarrhythmic properties of 7-benzyl-3-thia-7-azabicyclo[3.3.1]nonane-9-one, 7-benzyl-3-thia-7-azabicyclo[3.3.1] nonane hydroperchlorate, and 7-benzyl-9-phenyl-3-thia-7-azabicyclo[3.3.l]nonan-9-ol hydroperchlorate and derivatives: single crystal X-ray diffraction analysis and evidence for chair-chair and chair-boat conformers in the solid state, Journal of Medicinal Chemistry, 27, pp

[3]

Bigger J.T., Hoffman B.F., Antiarrhythmic drugs, The pharmacological basis of therapeutics, pp. 748-783, (1985)

[4]

Bourne D.W.A., Multiforte, a microcomputer program for modelling and simulation of pharmacokinetic data, Computer Methods and Programs in Biomedicine, 23, pp. 277-281, (1986)

[5]

Boxenbaum H.G., Riegman S., Elashoff R.M., Statistical estimations in pharmacokinetics, Journal of Pharmacokinetics and Bio-pharmaceutics, 2, (1974)

[6]

Edwards C.H., Penny D.E., In Calculus and analytical geometry, (1982)

[7]

Gustafsson L.L., Walker O., Alvan G., Beermann B., Estevez F., Disposition of chloroquine in man after single intravenous and oral doses, British Journal of Clinical Pharmacology, 15, pp. 471-479, (1983)

[8]

McGovern B., Garan H., Kelley E., Adverse reactions during treatment with amiodarone hydrochloride, British Medical Journal, 287, pp. 175-180, (1983)

[9]

Nygaarde T.W., Sellers D., Cook T.S., DiMarco J.P., Adverse reactions to antiarrhythmic drugs during therapy for ventricular arrhythmias, Journal of the American Medical Association, 256, pp. 55-57, (1986)

[10]

Rakhit A., Holford N.H.G., Guentert T.W., Maloney K., Riegelman S., Pharmacokinetics of quinidine and three of its metabolites in man, Journal of Pharmacokinetics and Biopharmaceutics, 12, pp. 1-21, (1984)

← 1 2 →